Get the Stockscreener App
22.48
3.69%
0.625
Mbx Biosciences Inc stock is traded at $22.48, with a volume of 68,236.
It is up +3.69% in the last 24 hours and down -4.56% over the past month.
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$21.86
Open:
$22
24h Volume:
68,236
Relative Volume:
0.97
Market Cap:
$729.77M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.69%
1M Performance:
-4.56%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$20.98
$22.95
1-Week Range:
$20.98
$23.71
52-Week Range:
$19.33
$26.19
Mbx Biosciences Inc Stock (MBX) Company Profile
Mbx Biosciences Inc Stock (MBX) Latest News
MBX Biosciences (NYSE:MBX) Shares Gap DownTime to Sell? - MarketBeat
MBX Biosciences (NYSE:MBX) Shares Up 6.8%Should You Buy? - MarketBeat
MBX Biosciences (NYSE:MBX) Sets New 52-Week LowTime to Sell? - MarketBeat
MBX Biosciences to Participate in Upcoming November Investor Conferences - GlobeNewswire
MBX Biosciences (NYSE:MBX) Shares Down 4.5%Here's What Happened - MarketBeat
MBX Biosciences sets IPO terms with plans to raise up to $136 million - MSN
MBX Biosciences, Inc.'s Quiet Period Set To Expire on October 23rd (NYSE:MBX) - MarketBeat
MBX Biosciences, Inc.’s Quiet Period Set To Expire on October 23rd (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Stock Price Down 4%Here's Why - MarketBeat
MBX Bio drops despite bullish views on Street - MSN
MBX Biosciences (NYSE:MBX) Shares Up 4.6%Here's What Happened - MarketBeat
MBX Biosciences earns Buy rating at three investment firms - MSN
MBX Bio stock drops despite bullish initiations (NASDAQ:MBX) - Seeking Alpha
MBX Biosciences (NYSE:MBX) Shares Gap UpHere's Why - MarketBeat
Guggenheim bullish on MBX Biosciences stock, driven by MBX 2109 potential - Investing.com Canada
MBX Biosciences outlook solid with JPMorgan's overweight rating, eyes key catalysts in next 12 months - Investing.com India
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements - Investing.com India
MBX Biosciences earns Buy rating at three investment firms By Investing.com - Investing.com Canada
Guggenheim Begins Coverage on MBX Biosciences (NYSE:MBX) - Defense World
MBX Biosciences (NYSE:MBX) Now Covered by JPMorgan Chase & Co. - MarketBeat
Jefferies sees upside in MBX Biosciences stock, highlights PEP platform advancements By Investing.com - Investing.com South Africa
MBX Biosciences (NYSE:MBX) Stock Price Down 3.5%Should You Sell? - MarketBeat
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ - GlobeNewswire
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting - Yahoo Finance
MBX Biosciences (NYSE:MBX) Trading Down 4.1% - MarketBeat
MacroGenics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationMGNX - PR Newswire
HighVista Strategies LLC Lowers Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Shareholders that lost money on MacroGenics, Inc.(MGNX) Urged to Join Class ActionContact The Gross Law Firm to Learn More - Lelezard
330 Shares in Monolithic Power Systems, Inc. (NASDAQ:MPWR) Bought by Brighton Jones LLC - Defense World
Westwood Holdings Group Inc. Grows Holdings in Mplx Lp (NYSE:MPLX) - Defense World
Hagens Berman Reminds MacroGenics (MGNX) Investors of the Pending Class Action Lawsuit with a Lead Plaintiff - EIN News
MGNX Deadline: MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit - Lelezard
Bridges Investment Management Inc. Invests $2.87 Million in Mplx Lp (NYSE:MPLX) - Defense World
Mplx Lp (NYSE:MPLX) Shares Acquired by Parallel Advisors LLC - Defense World
Upstream Bio goes public amid spate of IPOs - The Pharma Letter
Life Sciences X. L.P. Frazier Acquires 625,000 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock - Defense World
Edward T. Mathers Purchases 500,000 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock - Defense World
Tuesday's Insider Trades: Major Buys at MBX Biosciences, Sells at Palantir By Investing.com - Investing.com South Africa
Tuesday's Insider Trades: Major Buys at MBX Biosciences, Sells at Palantir - Investing.com India
Private Advisor Group LLC Has $660,000 Stock Holdings in Monolithic Power Systems, Inc. (NASDAQ:MPWR) - Defense World
Barclays Lowers Mplx (NYSE:MPLX) Price Target to $45.00 - Defense World
WINTON GROUP Ltd Makes New $633,000 Investment in Monolithic Power Systems, Inc. (NASDAQ:MPWR) - MarketBeat
MBX Biosciences insider purchases $8 million in company stock By Investing.com - Investing.com South Africa
MBX Biosciences insider buys $8 million in company stock By Investing.com - Investing.com South Africa
MBX Biosciences insiders purchase $10 million in stock By Investing.com - Investing.com South Africa
MBX Biosciences director buys $8 million in company stock - Investing.com India
MBX Biosciences director buys $8 million in company stock By Investing.com - Investing.com Australia
MBX Biosciences insider purchases $8 million in company stock - Investing.com
MBX Biosciences insider buys $8 million in company stock - Investing.com
Mbx Biosciences Inc Stock (MBX) Financials Data
There is no financial data for Mbx Biosciences Inc (MBX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):